Hepatocyte-like Cells via FOXA3 and HNF4A Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant demand for human hepatocytes or hepatocyte-like cells for treating liver disorders and diseases, but the supply of cadaveric livers and functional hepatocytes is limited, and existing methods for generating human hepatocytes through lineage reprogramming face challenges such as resistance in human cells and proliferation arrest.
Innovation Solution
A method involving the forced expression of FOXA and HNF polypeptides, specifically FOXA3 and HNF4A, in non-hepatic human cells to generate hepatocyte-like cells, along with strategies to enhance cell proliferation and reduce apoptosis or senescence, such as using SV40 large T antigen and reducing Rb family gene expression, to produce cells with mature hepatic functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If lineage reprogramming is used to generate human hepatocytes, then hepatocyte-like cells can be produced, but human cells are resistant to reprogramming and proliferation arrest occurs
Solution Approach 1:
The patent changes the parameters of the reprogramming process by using a specific combination of transcription factors (FOXA3, HNF4A, HNF1A) and controlling their expression timing and levels. This optimized parameter set overcomes human cell resistance to reprogramming while maintaining proliferation capacity, resolving the contradiction between reprogramming efficiency and cell viability.
Solution Approach 2:
The patent introduces intermediate transcription factors that mediate the conversion process. These factors serve as intermediaries between the starting non-hepatic cells and the target hepatocyte state, facilitating gradual lineage conversion while maintaining cell proliferation, thus resolving the resistance and arrest issues.
2Quantity of substance
If more hepatocyte-like cells are generated to meet demand, then supply for therapy and research increases, but cadaveric liver supply is limited
Solution Approach 1:
The patent creates copies of functional hepatocytes by reprogramming non-hepatic human cells (such as fibroblasts) to become hepatocyte-like cells. This copying approach bypasses the limited supply of cadaveric livers and enables scalable production of hepatocytes for therapeutic and research applications.
Solution Approach 2:
The patent uses a universal reprogramming approach that can convert various non-hepatic cell types into hepatocyte-like cells. This multi-functional method allows selection from multiple starting cell sources, enhancing scalability and flexibility in producing hepatocytes to meet growing demand.
3Quantity of substance
If existing reprogramming methods are used, then some cell conversion is achieved, but trans-differentiated cells are proliferation arrested
Solution Approach 1:
The patent performs preliminary actions by carefully selecting and combining specific transcription factors before initiating full reprogramming. This preliminary setup includes using FOXA3, HNF4A, and HNF1A in a controlled sequence, which prepares the cells for conversion while preserving proliferation pathways, thus avoiding proliferation arrest.
Solution Approach 2:
The patent employs dynamic control of transcription factor expression during the reprogramming process. By adjusting expression levels and timing of FOXA3, HNF4A, and HNF1A, the method dynamically balances differentiation and proliferation signals, enabling generation of hepatocyte-like cells that retain expansion capability.
Data Source
AI summary
The present invention relates to hepatocyte-like cells. Also disclosed are methods of making the cells and using the cells.